IPO
Filter News
Found 17,230 articles
-
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - June 04, 2021
6/4/2021
Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 140,861 restricted stock units of Atara’s common stock to 28 newly hired employees and stock options to purchase an aggregate of 124,966 shares of Atara’s common stock to 7 such newly hired employees.
-
Getinge grows with social funding
6/4/2021
Getinge has launched a new framework for social financing and a new social bond of SEK 570 million. The capital will be used to expand the production capacity of products that save lives.
-
Surgalign Holdings, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - June 04, 2021
6/4/2021
Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, announced that it has granted equity awards to six employees, none of whom are executive officers, as an inducement for them to accept employment with Surgalign, and representing the right to purchase or receive, in the aggregate, up to 179,667 shares of Surgalign common stock.
-
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021
6/4/2021
G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 44,200 shares of G1’s common stock to five employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.
-
Optimus Healthcare Services Announces FINRA Approval for Corporate Name Change
6/3/2021
Optimus Healthcare Services, Inc. announced that it received approval notification from the Financial Industry Regulatory Authority for a corporate name change.
-
CooperCompanies Announces Second Quarter 2021 Results
6/3/2021
CooperCompanies announced financial results for its fiscal second quarter ended April 30, 2021.
-
Syneos Health Announces Pricing of Secondary Offering of Common Stock - June 03, 2021
6/3/2021
Syneos Health, Inc., the only fully integrated biopharmaceutical solutions organization, announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 10,851,676 shares of the Company’s common stock.
-
NeuroPace Reports First Quarter 2021 Financial Results and Provides 2021 Financial Guidance
6/3/2021
NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, reported financial results for the quarter ended March 31, 2021.
-
SOHM Receives Semi-Annual Order From Private Label Customer to Boost Anticipated Revenue for 2021
6/3/2021
SOHM, Inc., generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced that the Company has received a semi-annual, bi-monthly order for prescription skincare topical products, estimated to have a top-line revenue value of approximately $500k.
-
Nabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules Capital
6/3/2021
Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has reached an agreement with Hercules Capital, Inc. to extend principal payments under its existing loan agreement until at least January 1, 2022.
-
Ionis announces changes to its board of directors at annual meeting of stockholders
6/3/2021
Ionis Pharmaceuticals, Inc. announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board.
-
Stellanova Therapeutics, Inc. Announces Closing of $15.5 Million Series A Financing
6/3/2021
Proceeds will support development of antibody drugs and discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, rendering resistant cancers treatable
-
Operational Highlights and Financial Results for the Period Ended March 31, 2021
6/3/2021
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, reported operational highlights and financial results for the period ended March 31, 2021.
-
Services PMI® at 64%; May 2021 Services ISM® Report On Business®
6/3/2021
Economic activity in the services sector grew in May for the 12th month in a row, say the nation's purchasing and supply executives in the latest Services ISM® Report On Business®.
-
Medifast, Inc. Announces Quarterly Dividend - June 03, 2021
6/3/2021
Medifast, Inc., the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced that its Board of Directors has declared a $1.42 quarterly cash dividend to its stockholders.
-
Walgreens Boots Alliance Schedules Fiscal 2021 Third Quarter Earnings Announcement for July 1, 2021
6/3/2021
Walgreens Boots Alliance, Inc. will release its fiscal 2021 third quarter earnings results at 7 a.m. Eastern time Thursday, July 1, 2021 followed by a one-hour conference call with WBA management beginning at 8:30 a.m. Eastern time.
-
Cantel Medical LLC Announces Offer to Purchase Relating to Outstanding Convertible Senior Notes, Fundamental Change and Make-Whole Fundamental Change
6/3/2021
Cantel Medical LLC, formerly known as Cantel Medical Corp., announced that it has delivered a notice to holders of its 3.25% Convertible Senior Notes due 2025, pursuant to the indenture governing the Notes, notifying holders that, as a result of each of the consummation of the series of mergers contemplated by the Agreement and Plan of Merger, dated as of January 12, 2021
-
Asensus Surgical 2021 Annual Meeting of Stockholders Is Adjourned
6/3/2021
Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, announced that the Company’s 2021 Annual Meeting of Stockholders, scheduled to be held on Thursday, June 3, 2021 at 3:00 p.m., was adjourned to Tuesday, June 29, 2021 at 11:00 a.m.
-
ImaginAb completes $12.8 million financing to accelerate growth plans
6/3/2021
Latest financing will advance the clinical development of its CD8 ImmunoPET agent and build on its market leading position.
-
Immune Therapeutics Announces Financing and Debt Restructuring Plan
6/2/2021
Immune Therapeutics Inc. announced that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing Debt.